Valuation
Pharmaceutical PreparationsLive · Yahoo FinancePrice
$23.32
52-Week Range
Decision Context
Below-average scores in Quality, Efficiency, Cashflow. The data points to fundamental challenges that outweigh near-term macro considerations.
Based on filing period ending Mar 2026
FisclearScore is a quantitative model using public financial data and sector median benchmarks (refreshed monthly). Not financial advice. Always conduct independent due diligence.
Macro Context
SWOT Analysis — RCUS
Inflationary BoomStrengths
No standout strengths identified from the filing.
Weaknesses
Operating Cash Flow: -$482.0M (-183.5% YoY) — Negative operating cash flow — the business consumed more cash than it produced from operations.
Net Income: -$353.0M (-24.7% YoY) — The company posted a net loss — total expenses exceeded total revenue.
EPS (Diluted): $-3.29 (-4.8% YoY) — Negative EPS — the company recorded a loss on a per-share basis.
Revenue: $247.0M (-4.3% YoY) — Revenue fell 4% — the company generated less from its core operations.
Total Assets: $1.1B (-1.0% YoY) — Total assets shrank 1% — the balance sheet contracted.
R&D spending is 212% of revenue — heavy investment in future growth, but also a drag on current profitability.
Opportunities
No clear opportunities identified at this time.
Threats
Net loss of $353.0M — the company spent more than it earned. Investors should monitor the path to profitability.
Negative operating cash flow of $482.0M — the core business consumed more cash than it generated.
Financial Charts
Revenue vs Net Income
Margin Trend
Operating Cash Flow
Year-over-Year Changes
Operating Cash Flow
-$482.0M
was -$170.0M
Negative operating cash flow — the business consumed more cash than it produced from operations.
Net Income
-$353.0M
was -$283.0M
The company posted a net loss — total expenses exceeded total revenue.
EPS (Diluted)
$-3.29
was $-3.14
Negative EPS — the company recorded a loss on a per-share basis.
Revenue
$247.0M
was $258.0M
Revenue fell 4% — the company generated less from its core operations.
Total Assets
$1.1B
was $1.1B
Total assets shrank 1% — the balance sheet contracted.
Risk Flags
2 high · 0 medium · 1 low- ⚠ High
Net loss of $353.0M — the company spent more than it earned. Investors should monitor the path to profitability.
- ⚠ High
Negative operating cash flow of $482.0M — the core business consumed more cash than it generated.
- ○ Low
R&D spending is 212% of revenue — heavy investment in future growth, but also a drag on current profitability.
Price History
Technical Signals
Daily closes · 1-year dataLatest News
via FinnhubGet the weekly digest
5 company reports + macro context every week, free. No spam.
- Unlimited goal simulations
- 5 free company report summaries per day
- Weekly financial insights newsletter
External Links
Trade RCUS
Links open broker research pages. Not an endorsement or recommendation.
Research Arcus Biosciences, Inc.
Data sourced from SEC EDGAR, FRED (Federal Reserve Economic Data), and Yahoo Finance. For informational purposes only. Not financial advice.